المؤلفون: Rozeman, EA, Hoefsmit, EP, Reijers, ILM, Saw, RPM, Versluis, JM, Krijgsman, O, Dimitriadis, P, Sikorska, K, van de Wiel, BA, Eriksson, H, Gonzalez, M, Acosta, AT, Grijpink-Ongering, LG, Shannon, K, Haanen, JBAG, Stretch, J, Ch'ng, S, Nieweg, OE, Mallo, HA, Adriaansz, S, Kerkhoven, RM, Cornelissen, S, Broeks, A, Klop, WMC, Zuur, CL, van Houdt, WJ, Peeper, DS, Spillane, AJ, van Akkooi, ACJ, Scolyer, RA, Schumacher, TNM, Menzies, AM, Long, GV, Blank, CU

المصدر: Nature medicine. 27(2):256

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:145856821

المؤلفون: Helgason HH, Mallo HA, Droogendijk H, Haanen JG, van der Veldt AA, van den Eertwegh AJ, Boven E, Helgason, Helgi H, Mallo, Henk A, Droogendijk, Helga, Haanen, John G, van der Veldt, Astrid A M, van den Eertwegh, Alfonsus J, Boven, Epie

المصدر: Journal of Clinical Oncology; 1/1/2008, Vol. 26 Issue 1, p152-154, 3p

المؤلفون: Fraterman I; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Glaser SLC; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Informatics, Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Wilgenhof S; Department of Medical Oncology, Antoni Van Leeuwenhoek, Amsterdam, The Netherlands., Medlock SK; Department of Medical Informatics, Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., Mallo HA; Department of Medical Oncology, Antoni Van Leeuwenhoek, Amsterdam, The Netherlands., Cornet R; Department of Medical Informatics, Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands., van de Poll-Franse LV; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.; Department of Medical and Clinical Psychology, Center of Research On Psychological and Somatic Disorders (CoRPS), Tilburg University, Tilburg, the Netherlands., Boekhout AH; Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. a.boekhout@nki.nl.

المصدر: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2022 Sep; Vol. 30 (9), pp. 7249-7260. Date of Electronic Publication: 2022 May 19.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma*/therapy , Self-Management*/psychology , Telemedicine*, Humans ; Qualitative Research ; Quality of Life

المؤلفون: Rohaan MW; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gomez-Eerland R; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Berg JH; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Geukes Foppen MH; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Zon M; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Raud B; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Jedema I; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Scheij S; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Boer R; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bakker NAM; Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sari A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kessels R; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Haak M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Mallo HA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Karger M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Wiel BA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Zuur CL; Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands., Duinkerken CW; Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands., Lalezari F; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Thienen JV; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Wilgenhof S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Nuijen B; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

المصدر: Immuno-oncology technology [Immunooncol Technol] 2022 Jun 18; Vol. 15, pp. 100089. Date of Electronic Publication: 2022 Jun 18 (Print Publication: 2022).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 9918281581106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0188 (Electronic) Linking ISSN: 25900188 NLM ISO Abbreviation: Immunooncol Technol Subsets: PubMed not MEDLINE

المؤلفون: Rozeman EA; Departments of Medical Oncology., Prevoo W; Radiology, The Netherlands Cancer Institute (NKI), Amsterdam., Meier MAJ; Radiology, The Netherlands Cancer Institute (NKI), Amsterdam., Sikorska K; Department of Biometrics., Van TM; Division of Molecular Oncology and Immunology., van de Wiel BA; Department of Pathology., van der Wal JE; Department of Pathology., Mallo HA; Departments of Medical Oncology., Grijpink-Ongering LG; Department of Biometrics., Broeks A; Core Facility Molecular Pathology and Biobanking, NKI, Amsterdam, The Netherlands., Lalezari F; Radiology, The Netherlands Cancer Institute (NKI), Amsterdam., Reeves J; NanoString Technologies, Seattle, Washington, USA., Warren S; NanoString Technologies, Seattle, Washington, USA., van Thienen JV; Departments of Medical Oncology., van Tinteren H; Department of Biometrics., Haanen JBAG; Departments of Medical Oncology., Kapiteijn E; Department of Medical Oncology, LUMC, Leiden, The Netherlands., Blank CU; Departments of Medical Oncology.

المصدر: Melanoma research [Melanoma Res] 2020 Jun; Vol. 30 (3), pp. 252-260.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9109623 Publication Model: Print Cited Medium: Internet ISSN: 1473-5636 (Electronic) Linking ISSN: 09608931 NLM ISO Abbreviation: Melanoma Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*therapeutic use , Ipilimumab/*therapeutic use , Liver Neoplasms/*secondary , Liver Neoplasms/*therapy , Melanoma/*therapy , Radiofrequency Ablation/*methods , Uveal Neoplasms/*therapy, Adult ; Aged ; Combined Modality Therapy/methods ; Female ; Humans ; Male ; Melanoma/pathology ; Middle Aged ; Progression-Free Survival ; Uveal Neoplasms/pathology

SCR Disease Name: Uveal melanoma

المؤلفون: Blank CU; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl., Rozeman EA; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Fanchi LF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Wiel B; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kvistborg P; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Krijgsman O; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Braber M; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Philips D; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Broeks A; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Thienen JV; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Mallo HA; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Adriaansz S; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Ter Meulen S; Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Pronk LM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bruining A; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gittelman RM; Adaptive Biotechnologies, Seattle, WA, USA., Warren S; NanoString Technologies, Inc., Seattle, WA, USA., van Tinteren H; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., Peeper DS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JBAG; Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Akkooi ACJ; Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schumacher TN; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. t.schumacher@nki.nl.

المصدر: Nature medicine [Nat Med] 2018 Nov; Vol. 24 (11), pp. 1655-1661. Date of Electronic Publication: 2018 Oct 08.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

مواضيع طبية MeSH: Chemotherapy, Adjuvant/*methods , Ipilimumab/*administration & dosage , Melanoma/*drug therapy , Nivolumab/*administration & dosage, Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Chemotherapy, Adjuvant/adverse effects ; Disease-Free Survival ; Humans ; Ipilimumab/adverse effects ; Male ; Melanoma/pathology ; Melanoma/surgery ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Neoplasm Staging ; Nivolumab/adverse effects